Xanomeline-Trospium (KarXT) Shows Efficacy in Phase 3 Trial for Schizophrenia

The Psychopharmacology Institute is an online platform offering unbiased, practical psychopharmacology updates for healthcare providers, with content updated monthly. It also presents opportunities to earn CME and SA credits.
This volume features Dr. Freudenreich, who discusses a promising experimental antipsychotic named KarXT. This drug, currently in clinical trials, could revolutionize the treatment of schizophrenia by targeting the cholinergic system instead of the dopamine system as current treatments do.
Is this the start of a new phase in treating schizophrenia?
Find the transcript of this section here: psychopharmaco...
Did we mention you can also earn CME credits? This is something that you can take advantage of as a Silver or Gold member. Want to know more about Quick Takes and memberships? Click here: psychopharmaco...
#schizophreniatreatment #KarXT #AntipsychoticResearch #psychopharmacology

[@RynaxAlien]

When it will be available in EU?

[@susansmith9462]

My 23 year old son experienced his first episode of psychosis and subsequent diagnosis of schizophrenia 18 months ago with 3 hospitalizations and is presently on 6mg daily of risperidone and 1mg of Rexulti. He is no longer hearing voices but the weight gain,lethargy, and cognitive changes are painful for me to watch. I have read a little about KarXT and felt optimistic but recently his young psychiatrist told us he attended a conference and there was lots of discussion of KarXT and the takeaway was that it only shows some benefit for first time psychosis patients never treated with other antipsychotics and only as an adjunct to other antipsychotics. Needless to say I am a little confused from that and hope he is mistaken because I was hoping that it is improved in September and we could gradually transition him to KarXT with a lower dose of risperidone

[@constantinhaller4391]

Karxt can be tanken by itself and is very Strong on positiv Symptoms. We will See But it should be good.

[@constantinhaller4391]

There is a german Company making a med called evenamide it can cure Patients coming out in 2026

[@TheEclectic]

I can't wait to see this go up against risperidone, olanzapine, and olanzapine. As an inpatient psychiatrist, I probably won't be seeing this or using this with any of my patients any time soon, but hopefully its more effective than our current options and costs come down in the next few years!

[@therealhotchocolatecompany3962]

If KarXT becomes available, will I be able to stop abilify and go on KarXT?

[@Roberto11231]

If you have the money of course xD

[@wolfram9579]

Will it, or will it not, affect dopamine and serotonin levels?

[@constantinhaller4391]

Its coming out end in september

[@constantinhaller4391]

Better Wate for evenamide which can go into remission

[@Showtroupt2022]

Pills do not “treat” negative symptoms, there’s nothing to “lift”these are metabolic and mitocondrial dysfunction disorders of the brain and body. One new little drug that targets new mechanisms is a start but a pretty weak start. It is imperative that much better medications and brand new types of treatments are developed for all these people who have lost their lives and everything and everyone

[@spiralinandspiralout]

Keto diet?

[@Showtroupt2022]

@@spiralinandspiralout people want mono therapies, keto diet is a fantastic thing to add to other metabolic interventions. Keto doesn’t work by itself…people want legitimate treatments that target the debth and breadth of negative symptoms in schizophrenia